SUMMER NEWSLETTER 2021
Stemming the High and Rising Costs of Prescription Drugs

The Roger C. Lipitz Center for Integrated Health Care is pleased to share the newly released "Stemming the High and Rising Costs of Prescription Drugs" Issue brief in this Summer 2021 Lipitz Quarterly Newsletter.

POLICY INITIATIVES AND IMPACT
For over 5 years, faculty at the Roger C. Lipitz Center for Integrated Health Care based in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health have engaged in a multi-disciplinary initiative to understand the landscape and propose solutions to reduce prescription drug spending in America. Collaborating with decision makers and developing policies to reduce prescription drug spending without stifling innovation in the pharmaceutical industry is key. Learn more about how the Center is working with Congress, stakeholders with states, and aligning with the Federal Administration on policy initiatives.

SELECT PUBLICATIONS
Legislative initiatives are supported and elevated by peer-reviewed publications and detailed modeling led by the Center. Explore select papers authored by Center faculty, which are published in JAMA Network Open, American Journal of Public Health, JAMA Pediatrics, and Health Affairs.


IN THE MEDIA
Gerard Anderson (pictured left) was interviewed on NPR sharing why the skyrocketing cost of many prescription drugs in the U.S. can be blamed primarily on price increases, not expensive new therapies or improvements in existing medications as drug companies frequently claim. He was also mentioned in The Philadelphia Inquirer about the Pennsylvania proposal of a board to investigate increasing drug prices that residents can’t afford.

Mariana Socol is quoted in a MedPage Today article about a bill to let Medicare negotiate drug prices.

Jeromie Ballreich is quoted in a Healio article discussing the stability of NIH funding allocation over time.

So-Yeon Kang contributed to an article in Axios highlighting how higher prices drive up Medicare drug spending.